Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.
Shares of Recursion Pharmaceuticals RXRX are surging Wednesday following a robust earnings report released before the bell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results